Pfizer has applied for emergency approval of its COVID-19 vaccine from the India's drugs controller, the DGCI. The vaccine has already been granted emergency-use authorisation in the UK and Bahrain. Sources tell NDTV that, though unprecedented, Pfizer vaccine can get emergency approval in the country even without conducting a clinical trial if the DCGI is satisfied with the foreign trial data submitted. Experts, however, maintain that the logistical concerns of storage at -70 degrees Celsius and the $20 cost make it difficult for India to get the vaccine anytime soon.